March 1, 2018
Novavax plans Phase 2 trial of NanoFlu vaccine in third quarter of 2018
NanoFlu vaccine was well tolerated over the three-week trial period, Novavax said Thursday, adding it now expects to begin a…
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
March 1, 2018
Amarin Corporation’s cardiovascular study is nearing completion
Amarin Corporation’s REDUCE-IT cardiovascular study is nearing end, as the patients enrolled in it have begun the final study-related visits.
March 1, 2018
Basilea Pharmaceutica names Kaul as its Management Committee’s Chief Development Officer
Basilea Pharmaceutica has named Adesh Kaul as its Management Committee’s Chief Corporate Development Officer, who has been leading partnering activities…
March 1, 2018
Novartis and Pear Therapeutics work on prescription digital therapeutics for patients with schizophrenia and multiple sclerosis
Novartis and Pear Therapeutics will develop new treatments for patients with schizophrenia and multiple sclerosis, with Pear’s prescription digital therapeutics…
March 1, 2018
Gelesis bags $30 million to prepare for regulatory approval of its weight loss capsules
PureTech Health’s affiliate Gelesis has rasied $30 million to back bringing closer to shelves its pipeline of additinoal gastrointestinal disorders product candidates,…
February 28, 2018
EMA grants accelerated assessment for Shire’s Lanadelumab being evaluated for the prevention of attacks in Hereditary Angioedema patients aged 12 years and older
Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted an accelerated assessment for…
February 28, 2018
Novo Nordisk files for regulatory approval in the US and the EU for treatment of haemophilia A
Novo Nordisk has submitted a Biologics License Applications (BLA) to the US Food and Drug Administration (FDA) and a Marketing…
February 28, 2018
FDA rejects Celgene’s NDA for multiple sclerosis treatment
Celgene Corporation (NASDAQ:CELG) has received a Refusal to File letter from the United States Food and Drug Administration (FDA) regarding its New Drug…
February 28, 2018
AstraZeneca’s MedImmune to create stand-alone company for early-stage inflammation and autoimmunity biologics
AstraZeneca’s global biologics research and development arm, MedImmune, is spinning out six molecules from its early-stage inflammation and autoimmunity programmes…
February 28, 2018
Horizon Pharma submits supplemental New Drug Application for Ravicti oral liquid to expand age range to include newborns
Horizon Pharma plc (NASDAQ:HZNP) has submitted a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA)…